Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Napoli

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
Journal of Experimental & Clinical Cancer Research : CR|August 6, 2024
TFEB controls sensitivity to chemotherapy and immuno-killing in non-small cell lung cancerMuhlis Akman, Ciro Monteleone, Gabriella Doronzo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2022
Novel Lymphocyte-Independent Antitumor Activity by PD-1 Blocking Antibody against PD-1+ Chemoresistant Lung Cancer CellsRamona Rotolo, Valeria Leuci, Chiara Donini, et al.
Diagnostics (Basel, Switzerland)|July 27, 2022
Diagnostics of <i>BAP1</i>-Tumor Predisposition Syndrome by a Multitesting Approach: A Ten-Year-Long ExperienceMarika Sculco, Marta La Vecchia, Anna Aspesi, et al.
Neurology and Therapy|September 19, 2025
Real-World 24-Month Outcomes of Ofatumumab in Relapsing Multiple Sclerosis: Efficacy, Safety, and the Impact of FrailtyGina Ferrazzano, Roberta Fantozzi, Shalom Haggiag, et al.
Journal of Translational Medicine|March 11, 2026
Unraveling lung cancer dynamics: a new metabolic signature improving the prediction of recurrence in resected lung adenocarcinomaFrancesca Jacobs, Lorenzo Manganaro, Lorenzo D'Ambrosio, et al.
Multiple Sclerosis and Related Disorders|May 8, 2024
NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or NatalizumabElisabetta Signoriello, Alessio Signori, Giacomo Lus, et al.
CNS Drugs|May 29, 2025
Long-Term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder: A 5-Year Observational StudyGiovanni Novi, Francesca Bovis, Chiara Sciolla, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 18, 2024
Actionable NSCLC Mutation Identification by Comprehensive Genomic Profiling for Clinical Trial Enrollment: The European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA)Francesco Passiglia, Angela Listì, Paolo Bironzo, et al.
JACC. Advances|June 30, 2026
Tailoring Antiplatelet Therapy Duration After PFO Closure: Insights From the PROLONG RegistryCarlo Gaspardone, Daniela Trabattoni, Daniele O d'Atri, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 12, 2024
Maternal and fetal outcomes in an Italian multicentric cohort of women with multiple sclerosis exposed to dimethyl fumarate during pregnancyDoriana Landi, Silvia Bartolomeo, Francesca Bovis, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Journal of Experimental & Clinical Cancer Research : CR|August 6, 2024
TFEB controls sensitivity to chemotherapy and immuno-killing in non-small cell lung cancerMuhlis Akman, Ciro Monteleone, Gabriella Doronzo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2022
Novel Lymphocyte-Independent Antitumor Activity by PD-1 Blocking Antibody against PD-1+ Chemoresistant Lung Cancer CellsRamona Rotolo, Valeria Leuci, Chiara Donini, et al.
Diagnostics (Basel, Switzerland)|July 27, 2022
Diagnostics of <i>BAP1</i>-Tumor Predisposition Syndrome by a Multitesting Approach: A Ten-Year-Long ExperienceMarika Sculco, Marta La Vecchia, Anna Aspesi, et al.
Neurology and Therapy|September 19, 2025
Real-World 24-Month Outcomes of Ofatumumab in Relapsing Multiple Sclerosis: Efficacy, Safety, and the Impact of FrailtyGina Ferrazzano, Roberta Fantozzi, Shalom Haggiag, et al.
Journal of Translational Medicine|March 11, 2026
Unraveling lung cancer dynamics: a new metabolic signature improving the prediction of recurrence in resected lung adenocarcinomaFrancesca Jacobs, Lorenzo Manganaro, Lorenzo D'Ambrosio, et al.
Multiple Sclerosis and Related Disorders|May 8, 2024
NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or NatalizumabElisabetta Signoriello, Alessio Signori, Giacomo Lus, et al.
CNS Drugs|May 29, 2025
Long-Term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder: A 5-Year Observational StudyGiovanni Novi, Francesca Bovis, Chiara Sciolla, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 18, 2024
Actionable NSCLC Mutation Identification by Comprehensive Genomic Profiling for Clinical Trial Enrollment: The European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA)Francesco Passiglia, Angela Listì, Paolo Bironzo, et al.
JACC. Advances|June 30, 2026
Tailoring Antiplatelet Therapy Duration After PFO Closure: Insights From the PROLONG RegistryCarlo Gaspardone, Daniela Trabattoni, Daniele O d'Atri, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 12, 2024
Maternal and fetal outcomes in an Italian multicentric cohort of women with multiple sclerosis exposed to dimethyl fumarate during pregnancyDoriana Landi, Silvia Bartolomeo, Francesca Bovis, et al.
Pageof 7